Skip to main content

Breadcrumb

  1. Home

Comprehensive characterization of the biology of inflammatory bowel disease-associated colorectal cancer using the GeoMx® Digital Spatial Profiler (DSP)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Comprehensive characterization of the biology of inflammatory bowel disease-associated colorectal cancer using the GeoMx® Digital Spatial Profiler (DSP)

Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Actionable fusions detected by RNA-seq co-occur with PD-L1 expression and driver mutations in solid tumors patients

Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay

Plasma first: Accelerating lung cancer diagnosis through liquid biopsy

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Plasma first: Accelerating lung cancer diagnosis through liquid biopsy

Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC)

Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC

Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma

Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

PAK4 as a potential marker for poor response to immunotherapy in melanoma patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about PAK4 as a potential marker for poor response to immunotherapy in melanoma patients

Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 71
  • Page 72
  • Page 73
  • Page 74
  • Page 75
  • Page 76
  • Page 77
  • Page 78
  • Page 79
  • …
  • Next page Next
  • Last page Last
Subscribe to